The FDA reviewed the Biologics License Application (BLA) for MOGENRY, a gene therapy, involving Nanoscope Therapeutics, Inc.
2 reports, 1 independent
Updated Sep 11
Gone quiet
- Reports
- 2
- Developments
- 3
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
The FDA reviewed the Biologics License Application (BLA) for MOGENRY, a gene therapy, involving Nanoscope Therapeutics, Inc.
Who's involved
What this event is mainly aboutHow it developed
Newest first. Tap a step to see who reported it.- Christine Kay, MD, has been appointed as Director of Clinical Research at Nanoscope Therapeutics, Inc.Sub-event
Nanoscope Therapeutics details the development of MOGENRY, naming its CEO and the technology's inventor.1 source
FDA reviews BLA for MOGENRY gene therapy from Nanoscope Therapeutics.1 source
Keep exploring
The entities involved
Related events
- The FDA reviewed gene therapy applications and provided milestone payments for dosing involving Regenxbio and AbbVie.
- Solid Biosciences received FDA approval for a gene therapy trial on July 9, 2025.
- FDA placed a clinical hold on a gene therapy involving Hunter.
- The FDA approved various advanced therapies, including oral medication from Roche, a gene-targeting drug from Biogen, and a one-time gene therapy from Novartis.
- uniQure N.V. traded on the Nasdaq stock exchange and submitted a Biologics License Application (BLA) for accelerated approval of its gene therapy.